Servier and CTI Biopharma Announce Exclusive License and Collaboration Agreement to Develop and Commercialize Pixuvri

PRESS RELEASE

Suresnes, France, September 17, 2014 - Servier and CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today jointly announced and they have entered into and exclusive license and collaboration agreement to develop and commercialize PIXUVRI® (pixantrone).

 

Silahkan klik di sini untuk informasi lebih detail.

Contact :

CTI BioPharma Contact
Monique Greer
+1 206-272-4343
 
Servier Contact
Servier Communication Department
+33 1 5572 6037
-----------------------------------------------------------